Robert Percell, MD
Cardiovascular Disease · Lincoln, NENPI 1316025505
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $619,349 of the $918,317 with a category attached, or 67.4%. Abbott accounts for 88.5% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $339,690 and has fallen 89.3% since, to $36,472 in 2025. Among cardiovascular disease clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,087 payments — averaging $844.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$813K
- Johnson & Johnson$73K
- Siemens Medical Solutions USA, Inc.$22K
- E.r. Squibb & Sons, L.L.C.$7K
- Biosense Webster, Inc.$2K
- Boston Scientific$979
- plus $650 from 9 others
Across 151 payments — averaging $2611.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$357K
- Impulse Dynamics (USA) Inc.$37K
- Medtronic$189
What the payments were for
- Consulting fees$619,34967%
- Speaking & faculty fees$101,55011%
- Travel & lodging$176,85219%
- Food & beverage$20,5662%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 932 | $812,649 |
| Johnson & Johnson | 74 | $72,687 |
| Siemens Medical Solutions USA, Inc. | 18 | $21,748 |
| E.r. Squibb & Sons, L.L.C. | 5 | $7,255 |
| Biosense Webster, Inc. | 19 | $2,350 |
| Boston Scientific | 10 | $979 |
| Philips North America LLC | 5 | $167 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $110 |
| Preventice Services, LLC | 1 | $100 |
| Impulse Dynamics (USA) Inc. | 4 | $99 |
| Sanofi-aventis U.S. LLC | 4 | $69 |
| Itamar Medical Inc | 1 | $37 |
| Cardiofocus, Inc. | 1 | $30 |
| Pfizer | 2 | $23 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$525,211
- XARELTO$71,742
- Ensite Cardiac Mapping System$52,694
- AVEIR$50,149
- AMPLATZER$46,152
- Confirm Rx$15,902
- TactiCath Quartz CFA Catheter$11,699
- Quartet CRT Lead$11,175
- AMPLATZER PICCOLO$11,160
- Assurity Pacemaker$11,082
- Quadra Assura CRT Defibrillator$10,574
- ACUSON Origin Diagnostic Ultrasound System$10,131
- EP-WorkMate Claris System$7,875
- Accent Pacemaker$7,840
- ADVISOR$7,560
- ELIQUIS$7,242
- ACUSON SC2000 Diagnostic Ultrasound System$5,825
- ACCENT$5,000
- Anthem CRT Pacemaker$4,850
- Allure Quadra RF CRT Pacemaker$4,717
How this compares
$918,317 in reported general payments places this provider in the 95th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 405 | $309,421 |
| EliquisApixaban | 345 | $253,603 |
| MultaqDronedarone Hcl | 26 | $19,540 |
| Flecainide Acetate | 273 | $8,764 |
| Metoprolol Succinate | 515 | $5,787 |
| Nebivolol Hcl | 77 | $3,354 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 83 | $2,482 |
| SotalolSotalol Hcl | 90 | $1,396 |
| ClopidogrelClopidogrel Bisulfate | 191 | $1,357 |
| Amiodarone Hcl | 97 | $995 |
| Bisoprolol Fumarate | 14 | $469 |
| Metoprolol Tartrate | 130 | $450 |
| Carvedilol | 61 | $360 |
| Amlodipine Besylate | 66 | $261 |
| Cartia XtDiltiazem Hcl | 12 | $187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $72,687 | $309,421405 claims |
| PfizerEliquis | $23 | $253,603345 claims |
| Sanofi-aventis U.S. LLCMultaq | $69 | $19,54026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Lincoln
- Steven KruegerLincoln$388K
- Keith MillerLincoln$86K
- Wynn HunterLincoln$46K
- Gina MentzerLincoln$27K
- Rajeev AnchanLincoln$7K
- Kaliprasad AyalaLincoln$5K
- John SteuterLincoln$4K
- Rebecca RundlettLincoln$3K
- Omar NassLincoln$3K
- Chad TraversLincoln$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.